- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02482818
Efficacy of Pregabalin on Chronic Cough
Efficacy of Pregabalin on Chronic Cough: A Double Blind, Randomized Control Trial Comparing Pregabalin With Placebo in Patients With Non-asthmatic Chronic Cough
Study Overview
Detailed Description
A significant number of patients have an impaired quality of life due to chronic cough that fails to respond to therapeutic efforts.
Research suggests that patients with chronic cough may have an oversensitive cough reflex. Reflexes are involuntary responses to nerve stimulation. Since standard cough medicines may not be helpful for treating the oversensitive cough reflex, treatment with neurologically acting agents has been investigated.
Existing work in treatment of cough of unknown etiology has focused on the use of Gabapentin, a compound that acts neurologically that is used in the treatment of epilepsy and pain. A similar drug, Pregabalin, may be a superior medication for this indication. Pregabalin is rapidly absorbed with peak blood concentrations within 1 hour, has an approximate bioavailability of 90%, and is 3 to 10 times more potent than Gabapentin and has no known pharmacokinetic drug interactions.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- Recruiting
- The Ottawa Hospital (General and Civic Campuses)
-
Contact:
- Isabelle Seguin
- Phone Number: 613-737-8811
- Email: iseguin@ohri.ca
-
Principal Investigator:
- Kayvan Amjadi, MD
-
Sub-Investigator:
- Nha Voduc, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of non-asthmatic chronic cough defined as a cough experienced for a period of at least 8 weeks
- Negative methacholine challenge (within past year)
- Chest x-ray with absence of gross abnormality that could justify the cough or be a cause for the cough (within past 6 months)
- Male or female 18 years or older
- Willing and able to limit to 1 or less alcohol beverage per day (example: 360 ml of beer or 330 ml of cooler or 120 ml of wine)
Exclusion Criteria:
- Concurrent use of Gabapentin or Pregabalin for other indications (seizure disorder, chronic pain)
- History of allergy / intolerance or adverse effect with Gabapentin or Pregabalin.
- Concurrent use of central nervous system depressants (i.e. opioids or benzodiazepines)
- Not able to limit daily alcohol intake as recommended in the inclusion criteria
- Creatinine clearance < 60ml/min within past three months
- Current Smoker or has been quit less than 8 weeks
- Symptoms of post nasal drip
- History of gastroesophageal reflux. Only participants with untreated Gastroesophageal Reflux Disease (GERD) or less than 8 weeks of therapy will be excluded.
- Symptoms of upper airway cough syndrome
- ACE inhibitor use
- Allergy to citric acid
- Pregnant or nursing women
- History of angioedema or congestive heart failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control-Placebo
Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial. Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days). Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day. Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42. |
A control substance, Lactose is administered in place of Pregabalin.
Other Names:
|
Experimental: Pregabalin
Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial. Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days). Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day. Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days. Forty two days after initial drug administration the Doctor will meet with subjects to follow up. |
Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the impact of pregabalin on a cough specific quality of life questionnaire (Leicester Cough Questionnaire)
Time Frame: 42 days
|
All patients will be required to fill out the questionnaire in the follow up visits.
This questionnaire is validated, reliable and subjective method for assessing the response to therapy
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the impact of pregabalin on cough reflex sensitivity, which can be objectively measured using citric acid cough challenge
Time Frame: 42 days
|
Citric acid has been used extensively in the literature as an effective inhaled compound that can induce cough.
The changes in the concentration of citric acid that can cause 2 or 5 consecutive coughs (C2 or C5) has been used to objectively determine the impact of various therapies on cough receptors.
|
42 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kayvan Amjadi, MD, Ottawa Hospital Research Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Cough
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Pregabalin
Other Study ID Numbers
- 2011734-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cough
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Respivant Sciences GmbHRespivant Sciences Inc.TerminatedChronic Cough | IPF | Persistent Cough in IPFUnited States, United Kingdom, Netherlands, Australia, Belgium, New Zealand, Turkey, Italy, Germany, Czechia, Canada
-
The First Affiliated Hospital of Zhejiang Chinese...Completed
-
ILiAD BiotechnologiesCompletedPertussis/Whooping Cough | Bordetella Pertussis, Whooping CoughUnited Kingdom
-
KK Women's and Children's HospitalSingapore University of Technology and DesignUnknownCough | URTI | Cough Variant Asthma | Cough; Bronchial, With Grippe or InfluenzaSingapore
-
Shanghai Zhongshan HospitalNot yet recruitingSufentanil-induced Cough
-
Merck Sharp & Dohme LLCCompletedChronic CoughCanada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
-
Khon Kaen UniversityCompleted
-
PhytoHealth CorporationCompleted
Clinical Trials on Control-Placebo
-
Yooyoung Pharmaceutical Co., Ltd.RecruitingDyslipidemiasKorea, Republic of
-
Vanda PharmaceuticalsCompleted
-
SIMR (Australia) Biotech Pty Ltd.CompletedPeripheral Neuropathic PainAustralia
-
PfizerNot yet recruiting
-
Affiris AGCompletedAlzheimer's DiseaseFrance, Austria, Croatia, Germany, Czech Republic, Slovakia
-
Cellphire Therapeutics, Inc.Department of Health and Human ServicesCompleted
-
Nature Cell Co. Ltd.CompletedAlzheimer DiseaseUnited States
-
Promius Pharma, LLCTerminatedOnychomycosisUnited States
-
TotipotentRX Cell Therapy Pvt. Ltd.TotipotentRX CorporationUnknownAcute Myocardial InfarctionIndia
-
Nature Cell Co. Ltd.RecruitingOsteoarthritis, KneeUnited States